AlzChem plans to “significantly increase” its nitroguanidine capacity, with a new production plant that will almost double the €76 million expansion it announced in the spring. It will also renew and expand its existing facilities for the precursor, guanidine nitrate, in what CEO Andreas Niedermaier called “the largest investment in our company’s history in Germany to date”.